Green technology,<BR>creating a better life.

Green technology,
creating a better life.

GREEN TECHNOLOGY, CREATE BETTER LIFE

Green technology,<BR> creating a better life.

Green technology,
creating a better life.

GREEN TECHNOLOGY, CREATE BETTER LIFE

Green technology, <BR>creating a better life.

Green technology,
creating a better life.

GREEN TECHNOLOGY, CREATE BETTER LIFE

ABOUT US

ABOUT US

SyncoZymes (Shanghai) Co., Ltd. is founded in 2007 and located in southern district of Shanghai Pudong Zhangjiang High-tech Park, the International Medical Park. SyncoZymes (Shanghai) is a subsidiary company of SyncoZymes (Zhejiang) Co., Ltd. SyncoZymes is committed to the research and development of cutting-edge technologies and products in the field of green pharmaceuticals, leading the development of the chemical pharmaceutical industry with green biotechnology, and providing high-quality products and services to the customers of pharmaceutical and healthy industry.

Learn more

Image Name
Image Name
100 + Enzymes

Enzyme Systems

Biocatalysis expert

Image Name
10000 + Enzymes

Enzymes

Large Enzyme Library open to customer

Image Name
1200 + Tons

Tons

Annual Capacity of Enzymes and Coenzymes

Image Name
160 + Pieces

Pieces

Apply for a patent

  • Enzymes
    SyncoZymes has a large enzyme library with 40 series and more than 10,000 enzymes, which can be applied to various types of chemical transformation reactions. Each type of enzyme can be made into enzyme plate for high-throughput screening. The company provides enzyme plate screening services, as well as the development of enzymes for biotransformation, the design and optimization of biotransformation processes, and the transfer of strains.
  • Co-enzymes
    SyncoZymes supplies co-enzyme of NAD series products, including NMN, NAD, NADP, NADH, NADPH, with an annual output of 100 tons, is one of the main suppliers of NAD-family coenzyme products in the world.
  • Functional Food Raw Materials
    SyncoZymes uses biocatalysis technology to develop green natural functional food raw materials, and produces them in strict accordance with the pharmaceutical standard system. It continuously explores the effects and mechanisms of natural ingredients on human health, realizes the green manufacturing of natural ingredients and provides scientific, safe and effective health for human beings.
  • Pharmaceutical Intermediates
    SyncoZymes has a strong biotechnology platform, chemical technology platform and GMP production system, focusing on the development and application of biological enzymes, focusing on the research and development and production of pharmaceutical intermediates.
  • CRO/CDMO Services
    SyncoZymes has a strong biotechnology platform, chemical technology platform, testing and quality research platform and GMP production system, focusing on the development and application research of biological enzymes, focusing on the research and development and application of green biotechnology pharmaceutical intermediates, APIs, functional food raw materials. At the same time, She provides high-end CRO, CDMO services, testing and quality research services.
  • Testing and Quality Research Services
    SyncoZymes undertakes the management and operation of the R&D public service platform in Shanghai International Medical Park, and can provide testing and quality research services for small molecule drug research and development. SyncoZymes equipped with NMR, LCMS, GCMS, HPLC, GC, protein purification, crystal form detection, preparative chromatography and other instrument.
Products and services
SyncoZymes (Shanghai) Co., Ltd., has a strong biotechnology platform, chemical technology platform, testing and quality research platform and GMP production platform. SyncoZymes focuses on the developing and applicating of biological enzymes and biocatalysis technologies, as well as synthetic biology technologies. SyncoZymes' main business is the research, development, production and sales of enzymes, co-enzymes, pharmaceutical intermediates, and functional food raw materials, and provides high-end CRO, CDMO services, testing and quality research services for customers.
Learn more

R&D system

R & D system

News

NEWS

Learn more

Good news! The TGA has approved Shangke Bio’s NMN raw material for use as a dietary supplement ingredient.

11

2025-12

Good news! The TGA has approved Shangke Bio’s NMN raw material for use as a dietary supplement ingredient.

On December 10, 2025, the Australian Therapeutic Goods Administration (TGA) approved Shangke Bio’s NMN raw material for use as an ingredient in complementary medicines and granted it a two-year period of market exclusivity (from December 10, 2025, to December 10, 2027). This decision officially permits Shangke Bio’s NMN raw material to be manufactured, marketed, and promoted in Australia as an ingredient in complementary medicines. The official notification can be found in the TGA’s regulatory document “Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2025,” under registration number 3488. Under the TGA’s regulatory framework, products analogous to China’s “health foods” or the U.S.’s “dietary supplements” are collectively classified as “complementary medicines.” This category encompasses traditional nutritional supplements such as vitamins, minerals, and herbal products, distinguishing them from therapeutic medicines like “prescription drugs” and “over-the-counter drugs.”

21

2026-09

Cutting-edge research progress: Experimenta & Molecular Medicine publishes findings showing that NMN activates sirtuins to ameliorate cardiovascular aging.

Findings by researchers at Central South University indicate that low levels of the Sirtuin‑7 protein are associated with the pathogenesis of AAA. Sirtuin‑7 is an NAD⁺‑dependent deacetylase that relies on NAD⁺ to catalyze protein deacetylation. Consequently, elevating NAD⁺ levels may help compensate for the reduced expression of Sirtuin‑7 by enhancing its deacetylase activity.

07

2026-08

Cosmetics publishes research findings: NMN can reverse hair loss in middle-aged individuals.

Aging, stress, and malnutrition can lead to hair thinning, thereby reducing people’s quality of life.

03

2026-07

MK-0616 (Enlicitide): Progress in API Synthesis Process Development

MK-0616 (Enlicitide) targets PCSK9 and is indicated for the treatment of hypercholesterolemia, familial hypercholesterolemia, and other related conditions.

18

2026-03

[Good News] Shangke Bio (Shanghai) has successfully passed the re‑review for National High‑Tech Enterprise certification (for the 2025 fiscal year).

On December 25, 2025, the Office of the National Leading Group for the Administration of High-Tech Enterprise Recognition published the list of the second batch of high-tech enterprises recognized in 2025. Shangke Biopharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as “Shangke Bio”) successfully passed the re‑review for national high‑tech enterprise certification (No. 799).

×
视频标题